Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/5/2025 | $3.75 → $0.40 | Overweight → Neutral | Piper Sandler |
| 11/15/2024 | Neutral → Underperform | BofA Securities | |
| 10/14/2024 | Buy → Neutral | BofA Securities | |
| 8/16/2023 | Market Perform | SVB Securities | |
| 8/15/2023 | $20.00 | Overweight | Piper Sandler |
| 8/15/2023 | $18.00 | Buy | BofA Securities |
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported
8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
SC14D9C - Turnstone Biologics Corp. (0001764974) (Subject)
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t
Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously
BofA Securities downgraded Turnstone Biologics from Neutral to Underperform
BofA Securities downgraded Turnstone Biologics from Buy to Neutral
SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)